2. Signaling Pathways
  3. Immunology/Inflammation
  4. CTLA-4

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4; CD152

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9901
    Ipilimumab
    		Inhibitor 99.88%
    Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.
    Ipilimumab
  • HY-108829
    Abatacept
    		≥99.0%
    Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
    Abatacept
  • HY-P9918
    Tremelimumab
    		99.50%
    Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
    Tremelimumab
  • HY-P99132
    Anti-Mouse CTLA-4 Antibody (9D9)
    		≥98.0%
    Anti-Mouse CTLA-4 Antibody is an anti-mouse CTLA-4 IgG2b antibody inhibitor derived from host mouse.
    Anti-Mouse CTLA-4 Antibody (9D9)
  • HY-P99117
    Cadonilimab
    		Inhibitor
    Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
    Cadonilimab
  • HY-P99943
    Erfonrilimab
    Erfonrilimab (KN-046) is an anti-PDL1/CTLA-4 monoclonal antibody.
    Erfonrilimab
  • HY-P990703
    Porustobart
    Porustobart is an anti-CTLA4 monoclonal antibody.
    Porustobart
  • HY-P990739
    Evalstotug
    Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Evalstotug
  • HY-P99166
    Vudalimab
    		Inhibitor ≥99.0%
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
    Vudalimab
  • HY-108829A
    Abatacept (powder)
    		Inhibitor
    Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.
    Abatacept (powder)
  • HY-P99484
    Botensilimab
    		Inhibitor
    Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer.
    Botensilimab
  • HY-P99514
    Zalifrelimab
    		Inhibitor 98.28%
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.
    Zalifrelimab
  • HY-P990042
    Gotistobart
    		Inhibitor 98.00%
    Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment.
    Gotistobart
  • HY-P99760
    Nurulimab
    		Inhibitor
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.
    Nurulimab
  • HY-P990041
    Firastotug
    		Inhibitor
    Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer.
    Firastotug
  • HY-P990048
    Muzastotug
    		Inhibitor
    Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic.
    Muzastotug
  • HY-P99844
    Davoceticept
    Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells.
    Davoceticept
  • HY-P99809
    Quavonlimab
    		Inhibitor ≥99.0%
    Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody.
    Quavonlimab
  • HY-P99540
    Tuvonralimab
    		Inhibitor 99.14%
    Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab.
    Tuvonralimab
  • HY-P990080
    Sovipostobart
    		Inhibitor
    Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic.
    Sovipostobart
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity